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Abstract
Objectives—To elucidate the genetic variability between heavy drinkers with and without 
alcoholic hepatitis.
Materials and methods—An exploratory genome-wide association study (GWAS; 
NCT02172898) was conducted comparing 90 alcoholic hepatitis cases with 93 heavy drinking 
matched controls without liver disease in order to identify variants or genes associated with risk 
for alcoholic hepatitis. Individuals were genotyped using the Multi-Ethnic Genotyping Array, after 
which the data underwent conventional quality control. Using bioinformatics tools, pathways 
associated with alcoholic hepatitis were explored on the basis of individual variants, and based on 
genes with a higher “burden” of functional variation.
Results—Although no single variant reached genome-wide significance, an association signal 
was observed for PNPLA3 rs738409 (p = 0.01, OR 1.9, 95% CI 1.1 – 3.1), a common single 
nucleotide polymorphism that has been associated with a variety of liver-related pathologies 
including alcoholic cirrhosis. Using the Improved-Gene Set Enrichment Analysis for GWAS tool it 
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was shown that, based on the single variants’ trait-association p-values, multiple pathways were 
associated with risk for alcoholic hepatitis with high confidence (FDR < 0.05), including several 
pathways involved in lymphocyte activation and chemokine signaling, which coincides with 
findings from other research groups. Several Tox Functions and Canonical Pathways were 
highlighted using Ingenuity Pathway Analysis, with an especially conspicuous role for pathways 
related to ethanol degradation, which is not surprising considering the phenotype of the genotyped 
individuals.
Conclusion—This preliminary analysis suggests a role for PNPLA3 variation and several gene 
sets/pathways that may influence risk for alcoholic hepatitis among heavy drinkers.
Keywords
alcoholic hepatitis; genome-wide association study; genetic risk; single nucleotide polymorphism; 
pathway enrichment
Introduction
Alcoholic hepatitis (AH) is an illness marked by liver inflammation triggered by excessive 
alcohol consumption over a prolonged period of time. It may be rapidly fatal and is often 
associated with fibrosis and the development of cirrhosis [1], which is life-threatening and 
can require liver transplantation [2]. Interestingly, only a minority of heavy drinkers develop 
alcoholic hepatitis and this differential risk is poorly understood [3]. One approach to 
understanding this difference is to examine the genetic variability between heavy drinkers 
with and without alcoholic hepatitis. In the current exploratory study, we describe a genome-
wide association study (GWAS) of alcoholic hepatitis. Although analysis of the AH-
associated signal for individual variants was one of the objectives, it is clear that this 
preliminary study is underpowered to solely attempt to obtain a genome-wide significant 
signal for a disease like alcoholic hepatitis. With the currently available sample size, we 
were more interested in identifying gene sets and pathways associated with AH, than 
individual variants. Analysis of our GWAS data sheds some light on the genetic 
predisposition to, and biology of, alcoholic hepatitis.
Materials and Methods
Study Cohort
The study was conducted on a cohort consisting of 90 AH cases and 93 heavy drinking 
controls without liver diseases who were of European descent and were enrolled 
prospectively into the ongoing TREAT Alcoholic Hepatitis Prospective Study 
(NCT02172898; registered at ClinicalTrials.gov). Alcoholic hepatitis was defined based on 
clinical, biochemical and histological (wherever appropriate) criteria as described in an 
earlier publication from the TREAT consortium [4]. This definition is largely consistent with 
a recent consensus definition proposed by the NIAAA Alcoholic Hepatitis Consortium 
Investigators [5]. Based on the history, individuals with AH were deemed to not have drug 
induced liver injury as a reason for their liver disease presentation. Heavy drinking controls 
were those with average daily alcohol consumption similar to that of AH cases but had 
normal AST or ALT (< 50 U/L), total bilirubin (< 1 mg/dL), platelet count (> 140,000/mm3) 
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and lacked physical examination evidence for significant alcoholic liver disease such as 
hepatosplenomegaly or ascites. Abdominal ultrasound or elastography was not performed on 
controls. All subjects signed the informed consent and a local institutional review board at 
each site approved the study protocol.
Demographic data, past medical history and routine blood tests were collected prospectively 
on all consented participants. The quantity and pattern of alcohol consumption were 
determined using the Alcohol Use Disorders Identification Test (AUDIT), and the Time Line 
Follow-Back (TLFB).
Genotyping
The Multi-Ethnic Genotyping Array (MEGA) (Illumina, San Diego, CA) was used to 
genotype individuals according to the manufacturer’s protocol. Genotyping was performed 
at the Mammalian Genotyping Core, University of North Carolina at Chapel Hill.
Data Quality Control
Our initial study population of 196 subjects of European ancestry was genotyped on the 
Illumina MEGA beadchip. Before quality control (QC), the raw number of single nucleotide 
polymorphisms (SNPs) was 1,705,969. SNPs were excluded based on the following criteria: 
1) missing genotyping rate > 0.01 both SNP-wise and sample-wise; 2) SNP missing rate 
associated with case/control status (p < 0.0001); 3) monomorphic SNPs. Individual subjects 
were excluded if: 1) the inbreeding coefficient was outside of the normal range; 2) identity 
by descent (IBD) values between any two individuals was > 0.2; or 3) they were outliers on 
principal component analysis (PCA) (defined as subjects whose values on any of the top 10 
PCs exceed 6 times the standard deviation). A detailed breakdown of the QC process is 
depicted in the Figure of Supplemental Digital Content 1. The final analysis-ready dataset 
contained 183 subjects (93 controls and 90 cases) and 819,401 SNPs.
Whole Genome Association Analysis
Single-variant tests for association were performed using an allelic Fisher’s exact test as 
implemented in PLINK v1.07 [6] employing the --fisher option. A standard threshold for 
statistical significance was applied (p < 5 × 10−8).
Collapsing Test of Genes
In the collapsing test of each gene, we collapsed all functional (defined as those with 
putative impact being "high" or "moderate" in SNPEff’s annotation system; see http://
snpeff.sourceforge.net/VCFannotationformat_v1.0.pdf for details) and rare (defined as those 
with minor allele frequency (MAF) ≤ 1% in the 93 controls) variants by creating a binary 
indicator variable for each subject, which is equal to 1 if the individual carries any rare 
variant in that gene and 0 otherwise. Fisher’s exact test was then used to test the association 
between case/control status and "burden" of rare variants carried by a gene. From a total of 
22,222 unique Ensembl IDs, 10,429 had qualifying variants based on aforementioned 
inclusion criteria and were thus tested. Note that a gene is ineligible for the test if no 
functional variants in the gene are observed in our data, or if their MAF in controls > 1%. 
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Using Bonferroni correction for multiple testing, and α = 0.05, the threshold for statistical 
significance in the gene-wise tests was p < 4.8 × 10−6.
Enrichment Test of a Gene Set
From the output of the gene collapsing test, we obtained a ranked list of p-values for all the 
genes tested. For a given gene set of interest (e.g., a particular pathway), we tested whether 
members of it are randomly distributed along the ranked list or tend to concentrate on the 
lower end (i.e., those showing stronger association with the case/control status). To this end, 
we applied the methodology of Gene Set Enrichment Analysis (GSEA) [7] by calculating an 
enrichment score (ES) for the given gene set, followed by estimating its statistical 
significance (nominal p-value) through a permutation test. We implemented GSEA in R 
following the procedure outlined in the Appendix of Subramanian et al., 2005, with 300 
permutations.
Obtaining Lists of SNPs Associated with Alcohol-Related Diseases
We used the GWAS Catalog at https://www.ebi.ac.uk/gwas to find SNPs shown to be 
associated with other alcohol-related diseases. The SNP Annotation and Proxy Search tool at 
https://www.broadinstitute.org/mpg/snap/ldsearch.php was used to find single variants in 
high linkage disequilibrium (LD) with SNPs of interest. Lists of proxies were generated 
using the 1000 Genomes Pilot 1 SNP data set, the CEU (Northern Europeans from Utah) 
population panel, an r2 threshold of 0.8, and a distance limit of 500kb. The Batch Coordinate 
Conversion (liftOver) tool at https://genome.ucsc.edu/cgi-bin/hgLiftOver was used to 
convert genome coordinates across different genome builds.
Pathway Analysis Tools
Improved-Gene Set Enrichment Analysis for Genome-Wide Association Study (i-
GSEA4GWAS) was used to obtain pathway information on as many variants and genes in 
our dataset as possible [8]. The disease association p-value of each variant and gene is 
incorporated into i-GSEA4GWAS’s analysis. The i-GSEA4GWAS tool implements GSEA 
through permutation of SNP labels, and uses an improved version of GSEA by focusing on 
gene sets with a large proportion of significant genes. In QIAGEN’s Ingenuity® Pathway 
Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity), we tested gene lists 
using a p-value threshold of 0.05 or 0.5. We considered experimentally observed, direct and 
indirect relationships in humans, from all of IPA’s data sources. The p-value associated with 
a function or pathway in IPA, calculated using the right-tailed Fisher Exact Test, indicates 
the likelihood that the function or pathway is associated with a set of focus genes due to 
random chance. In g:Profiler [9] and Gene Ontology enRIchment anaLysis and 
visuaLizAtion (GOrilla) [10] we uploaded our dataset of ranked genes using a trait 
association p-value cutoff of 0.05, and no cutoff, respectively. Both GOrilla and g:Profiler 
produce effective graphical representations, but the former generates output images based on 
enrichment of GO terms, whereas the latter performs functional profiling, biomolecule 
integration tasks and genomic data mining using additional databases such as those from 
KEGG, Reactome, GEO and BioGrid. The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7 [11] was used to gather additional information on our 
list of genes with a p-value < 0.05.
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Results
We genotyped a sample of 90 alcoholic hepatitis cases and 93 heavy drinking controls (see 
Table 1 for demographics and clinical characteristics) of European ancestry for 
approximately 1.7 million SNPs using the MEGA array. Based on this sample of 183 
subjects, no single genetic marker showed genome-wide significant association with 
alcoholic hepatitis (see Figure 1 for Manhattan plot; and Figure 2 for Quantile-Quantile 
plot). Although no single common or rare variant reached genome-wide significance, we 
proceeded to perform an exploratory analysis on the dataset of this GWAS of alcoholic 
hepatitis.
Immune-Mediated and Inflammatory Processes
I-GSEA4GWAS was used to assess whether gene sets are enriched on the basis of the p-
values of individual variants (see Tables a & b, Supplemental Digital Content 2, for detailed 
results; and Table 2a & b for condensed versions). Many immune-mediated and 
inflammatory processes appear to be associated with risk for alcoholic hepatitis with high 
confidence when assessing all SNPs within a range of 500kb upstream and downstream of 
genes. These processes include gene sets related to chemokines such as the CXCR4 
Pathway, and the CCR3 Pathway (each with p < 0.001; and False discovery rate (FDR) ≤ 
0.012). It has previously been shown that, in contrast to circulating neutrophils, infiltrating 
neutrophils express receptors for these chemokines [12]. Alcoholic hepatitis is characterized 
by neutrophils infiltrating the liver, and the regulation of these chemokine pathways may 
play a role in that regard. In addition, we observed enrichment of lymphocyte-related gene 
sets including Positive Regulation of T Cell Activation, Regulation of Lymphocyte 
Activation, Regulation of T Cell Activation, Positive Regulation of Lymphocyte Activation, 
Positive Regulation of T Cell Proliferation, T Cell Proliferation, and Regulation of T Cell 
Proliferation (each with p < 0.001; and FDR < 0.041); and the autophagy-related gene set 
HSA04140 Regulation of Autophagy (p < 0.001; FDR < 0.008). The observations by other 
research groups that cytotoxic T lymphocytes have impaired cytotoxicity and reduced 
activation in alcoholic hepatitis [13], and that alcohol-induced liver diseases are associated 
with upregulation of autophagy in hepatocytes [14] may be related to the enrichment of 
these pathways. In addition, the Nuclear Chromosome Part gene set was found to be 
associated with risk for alcoholic hepatitis with high confidence when evaluating all SNPs 
within a range of 500kb upstream and downstream of genes (p < 0.001; FDR < 0.001), or 
assessing only functional variants (e.g., nonsynonymous SNPs; those inducing a frame shift; 
those affecting an essential splice site) (p < 0.001; FDR = 0.049). Although the Nuclear 
Replication Fork gene set is associated with the trait with statistical significance when only 
considering functional SNPs (p < 0.001; FDR = 0.032), the gene set loses its significance 
after multiple testing correction when SNPs within a range of 500kb on either side of genes 
are taken into account (p = 0.007; FDR = 0.201). A total of 21 additional gene sets are 
enriched with high confidence based on SNPs within a range of 500kb upstream and 
downstream of genes. Masking all the genes in the extended region of the major 
histocompatibility complex (MHC) had a negligible effect on these associations.
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Comparison of Single Variant Data with Other Alcohol-Related GWASs
GWASs on other alcohol-related traits may hold clues about the genetic nature of alcoholic 
hepatitis, and/or of excessive alcohol consumption without developing alcoholic hepatitis 
(i.e., the control population in the current study). Using the NHGRI-EBI GWAS Catalog (at 
https://www.ebi.ac.uk/gwas) a list of all genome-wide significant SNPs associated with an 
alcohol-related phenotype was compiled, and subsequently divided into a list with 
pathological and a list with behavioral traits (see Tables a & b, Supplemental Digital Content 
3). A total of 24 unique SNPs were associated with behavioral phenotypes (e.g., alcohol 
consumption, alcohol dependence, alcoholism), and two SNPs with pathological phenotypes 
(pancreatitis). The 105 genome-wide significant SNPs identified in a recently published 
alcoholic cirrhosis GWAS [15] were not yet listed in the GWAS Catalog at the time of 
writing this manuscript - these were manually added to the list of SNPs associated with 
alcohol-related pathological traits. To increase the number of SNPs with which we can make 
comparisons between our dataset and the findings from other studies, we included variants 
in high LD with an r2 value of at least 0.8 (see Tables a & b, Supplemental Digital Content 
4).
Pathology-Associated SNPs
We compared the strength of SNP association between our alcoholic hepatitis cases versus 
controls, against the results seen in other studies which are similarly comparing patients with 
organ-related illnesses with controls (although no SNP in our study reached genome-wide 
significance, and only SNPs which reached at least genome-wide significance were selected 
from other studies; see Table b, Supplemental Digital Content 3). From the list of alcohol 
pathology-associated SNPs we compared, the variants with the strongest signal in our study 
were all at the PNPLA3 locus, of which many, such as the three with the highest signal 
(rs2294915, rs3747207, and rs738409) are in high LD (see Table b, Supplemental Digital 
Content 4). Previous studies have shown that one of these three top variants, rs738409 
(I148M), is an important risk variant for alcoholic cirrhosis, and this has recently been 
confirmed by a large alcoholic cirrhosis GWAS [15]. We were able to find an association of 
this SNP with alcoholic hepatitis as well (p = 0.01, OR 1.9, 95% CI 1.1 – 3.1), although our 
sample size was too small to show genome-wide significance. The overall MAF of rs738409 
was 0.339 in cases, and 0.215 in controls (see Table 3). Furthermore, there was no 
significant difference in rs738409 MAF (p-value > 0.05) between the 71 subjects with AH 
who survived compared to the 19 who died during the 12 month follow-up period (see Table 
4).
Alcohol-Related Behavior-Associated SNPs
Next, we took advantage of the fact that both our alcoholic hepatitis cases and the matched 
controls are heavy alcohol users, and therefore share a behavioral trait. This allowed us to 
genetically compare the 183 heavy alcohol users as a whole with subjects in the control 
dataset from the Wellcome Trust Case Control Consortium (WTCCC) (http://
www.wtccc.org.uk) GWAS, with the assumption that the WTCCC has a negligible 
proportion of heavy alcohol users. Only those SNPs which were studied in both our dataset 
and the one from the WTCCC were compared. None of the variants reached statistical 
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significance at α = 0.05 or 0.10 (see Figure, Supplemental Digital Content 5, for a Quantile-
Quantile plot; and Table a, Supplemental Digital Content 3). When including variants in 
high LD, we find three proxies of rs2168784 with a p-value between 0.05 and 0.10 (see 
Figure, Supplemental Digital Content 6, for a Quantile-Quantile plot; and Table a, 
Supplemental Digital Content 4). We were not able to compare rs2168784 directly between 
our sample and the WTCCC, because it was not genotyped on the MEGA array.
Gene-Based Tests for Burden of Functional Variation
Apart from focusing on individual variants, we performed gene-based tests to elucidate the 
“burden” of functional variation in patients with alcoholic hepatitis compared with matched 
controls. For these tests we only included rare variants (i.e., those with a MAF ≤ 1% in the 
controls) with obvious effects on protein structure or function (i.e., missense, nonsense and 
splice site variants). The rare variants in the current study map to a total of 10,429 unique 
Ensembl IDs (corresponding to 10,407 HUGO gene names) with qualifying variants (see 
Methods), 6,268 of which (60.1%) had a trait association p-value < 1 (see Table, 
Supplemental Digital Content 7). No single gene showed significant association after 
multiple testing correction, however, interestingly, among the top associated genes was 
SLC22A1, which is known to play a role in lipid metabolism in the liver [16].
Using various bioinformatics tools we explored which pathways may help characterize the 
differences between alcoholic hepatitis cases and matched controls from our dataset. Similar 
to the gene set enrichment assessment on the basis of the p-values of individual variants, we 
used i-GSEA4GWAS based on p-values of genes, where lower p-values imply a larger 
difference in being affected by rare variants between the two groups of subjects. As shown 
in the Table of Supplemental Digital Content 8, although some individual gene sets have an 
enrichment p-value ≤ 0.002, after multiple testing correction these gene sets are regarded as 
possibly associated with traits (i.e., FDR < 0.25), but none with statistical significance (i.e., 
FDR < 0.05). Masking an extended region of MHC again had negligible effect on the 
results.
Tox Functions
Using IPA we were able to identify several Tox Functions and Canonical Pathways, as well 
as various other signaling pathways – each of which might explain some of the differences 
between alcoholic hepatitis subjects and matched controls. In addition to using the IPA 
database as a reference set when running our analyses, we evaluated our dataset using itself 
as a reference. Since about half of all our original list of genes (22,222 Ensembl IDs, 
corresponding to 20,844 HUGO gene names) did not contain qualifying variants, the IPA 
database likely overestimates the degree of enrichment of pathways and gene sets. Using a 
relatively stringent association test p-value threshold of 0.05 and using the user dataset, or 
IPA database as reference, Liver Hyperplasia/Hyperproliferation was among highly enriched 
Tox Functions (see Figures, Supplemental Digital Content 9 & 10, respectively). Gene sets 
associated with Cardiac Arrhythmia, Kidney Failure, Liver Cirrhosis, Liver Fibrosis, 
Pulmonary Hypertension, Liver Inflammation/Hepatitis, and Liver Steatosis also reached 
statistical significance in our dataset.
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Ethanol and Other Degradation Pathways
Canonical Pathway enrichment became apparent only after loosening the inclusion criterion 
for the individual genes. By specifying the threshold of the alcoholic hepatitis association 
test p-value to be 0.5, nearly 5,000 unique genes are included in the core analysis, the 
maximum number of genes IPA recommends users to analyze for statistical reasons. Using 
the user dataset as reference, three out of the top four Canonical Pathways were involved in 
Ethanol Degradation, which might be an indication that alcohol metabolism plays an 
important role in describing differences between the cases and controls in our subject sample 
(see Figure, Supplemental Digital Content 11). A total of 84.2%, 90.0% and 83.3% of genes 
comprising the Ethanol Degradation II, Oxidative Ethanol Degradation III, and Ethanol 
Degradation IV Canonical Pathways, respectively, were on the list of genes below the p-
value cut-off (see Table, Supplemental Digital Content 12). Degradation of Noradrenaline 
and Adrenaline, Dopamine, Histamine, Putrescine, Tryptophan, Methionine, and Serotonin 
are among enriched Canonical Pathways as well. Using the IPA database as reference, the 
results look similar, albeit not identical (see Figure, Supplemental Digital Content 13).
To test the validity of these findings, we performed a disease/control relabeling permutation 
test of ten runs and assessed to what extent the aforementioned enrichments reappeared. 
Although the abovementioned pathways reached statistical significance in our true dataset, 
many permutations of the dataset reached statistical significance for the Tox Functions as 
well (see Figures, Supplemental Digital Content 9 & 10). None of the permutations reached 
statistical significance for any of the Ethanol Degradation Canonical Pathways, but some 
other Canonical Pathways were also enriched in one or more of our permutations (see 
Figures, Supplemental Digital Content 11 & 13). Although many permuted result sets did 
not reach the same level of significance as the true disease/control populations for the 
aforementioned pathways, the fact that some permutations did reach statistical significance 
suggests that no strong claims about the relevance of those pathways should be made in the 
context of alcoholic hepatitis.
Some support to the claim that there might be a true difference in enriched pathways 
between alcoholic hepatitis cases and matched controls, comes from the observation that 
each of the ten permutations had fewer genes which had an association test p-value < 0.5, 
implying that relabeling permutations may simply tend to dampen true biological differences 
between these populations.
Potential Enrichment of Additional Pathways
Examining pathway enrichment of gene classes that may contribute to risk for alcoholic 
hepatitis using the bioinformatics tools g:Profiler (see Figure, Supplemental Digital Content 
14), GOrilla (see Figures, Supplemental Digital Content 15, 16 & 17), and DAVID (see 
Tables a & b, Supplemental Digital Content 18) revealed the potential importance of a 
multitude of additional pathways. Gene sets related to the nuclear pore complex assembly, 
and alpha-actinin binding were shown to be enriched using g:Profiler and GOrilla. Apart 
from that, gene sets related to signaling, the cilium axoneme, and microtubule-associated 
components, among others, reappeared in the results of both GOrilla and DAVID.
Beaudoin et al. Page 8
Scand J Gastroenterol. Author manuscript; available in PMC 2018 January 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
This pilot report describes a GWAS of alcoholic hepatitis, but due to its limited sample size 
serves only as a proof of concept study of this understudied disease. This research was 
designed to find any kind of (preliminary) signal for individual variants, and to find 
potentially involved genes and pathways, which we were able to find. Although no 
individual SNP or gene was found to have a genome-wide significant association with the 
traits under study, various interesting observations were made which might prove important 
to the understanding of the underlying genetics of alcoholic hepatitis.
Since alcoholic hepatitis can result in cirrhosis, it would be prudent to evaluate whether 
specific variants are associated with risk for both phenotypes. Interestingly, the pivotal 
common SNP rs738409 in a recent alcoholic cirrhosis GWAS [15] was among the most 
strongly associated SNPs in our study as well, indicating that this may be a common risk 
factor for both alcoholic hepatitis and cirrhosis; in fact, it may suggest that PNPLA3 is 
associated with alcoholic cirrhosis via conferring increased sensitivity of the patient to 
alcoholic hepatitis. The current exploratory study provides optimism for expanded genome-
wide studies to be performed as additional patients are enrolled in and complete the TREAT 
trial. The fact that we see some evidence of association for rs738409, despite the currently 
small sample size, suggests that this common SNP may be among the strongest genetic risk 
factors for alcoholic hepatitis, as it is for alcoholic cirrhosis. However, rs738409 was far 
from being the SNP with the strongest signal in the current study, and it might turn out that 
other SNPs play a more important role in alcoholic hepatitis. It is furthermore important to 
note that we suspect a majority of AH cases to have significant underlying fibrotic disease, 
but without a biopsy it is difficult to be precise about the prevalence of underlying cirrhosis 
among AH cases. In the United States, routine liver biopsy is not standard of care in patients 
with AH, except when there is an uncertainty about the diagnosis, and thus a systematic 
histological characterization of our cases is lacking. This could have influenced the results in 
the current study.
By analyzing our dataset on a gene-based level, by only including variants which had a 
MAF ≤ 1% in our control population, we were able to elucidate which genes have the 
highest “burden” of functional variation in patients with alcoholic hepatitis compared with 
matched controls. Depending on which trait-association p-value cut-off we chose in pathway 
analysis tools, we obtained several interesting findings. For instance, we found several 
ethanol degradation pathways to be enriched in our dataset, which seems to agree with the 
traits under study. Similarly, the chemokine and lymphocyte activation pathways highlighted 
by iGSEA4GWAS are consistent with our current understanding of the role of infiltrating 
neutrophils and lymphocyte activity in hepatic inflammation.
The tools IPA, g:Profiler, GOrilla and DAVID showed enrichment of additional gene sets, 
some of which overlapped. An abundance of gene sets are highlighted by the various 
enrichment analysis methods used in the current study. Only after showing that enrichment 
of these pathways can be replicated in a new and/or larger cohort of alcoholic hepatitis 
patients and heavy drinking controls can we be confident that any of these are truly 
biologically important to alcoholic hepatitis.
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The ultimate goal of this pilot study was to find preliminary risk factors for alcoholic 
hepatitis, but apart from detecting a possible association of AH with PNPLA3, none of the 
reported GWAS results are statistically significant. The main limitation of the current study 
is clearly the small sample size, and thus future work with a larger number of subjects and 
the use of imputation approaches to increase the power to detect associations, as well as the 
inclusion of a validation cohort and/or the performance of appropriate functional assays, will 
be required in order to establish definite risk factors. While subjects are continuously being 
enrolled in the TREAT trial, it will take many more years before a study can be performed 
that is sufficiently powered to obtain results that can be clinically significant. However, the 
preliminary results found here might be reproduced with more power when such a study is 
possible, which will give those results increasing support. Finally, making these results 
available can benefit future research of this understudied disease, such as meta-analysis 
efforts.
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Figure 1. Manhattan plot for the current alcoholic hepatitis genome-wide association study
None of the single nucleotide polymorphisms reached genome-wide significance after 
Bonferroni multiple testing correction (dark grey line). The light grey line represents a p-
value of 1 × 10−5.
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Figure 2. Quantile-quantile plot for the alcoholic hepatitis genome-wide association study
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Table 1
Demographics of alcoholic hepatitis (AH) patients and heavy drinking matched controls without hepatitis.
Variables Controls (n = 93) AH cases (n = 90) p-value
Age (years) 44.6 ± 12.2 46.8 ± 11.0 0.21
Men, n (%) 56 (60%) 56 (62%) 0.78
BMI (kg/m2) 29.1 ± 7.3 29.6 ± 8.3 0.71
WBC (103 cells/mm3) 7.2 ± 2.8 11.1 ± 8.1 < 0.0001
Hemoglobin (g/dl) 13.3 ± 1.7 10.1 ± 1.9 < 0.0001
Platelet count (103 cells/mm3) 245.2 ± 71.9 139.3 ± 82.0 < 0.0001
Total bilirubin (mg/dL) 0.5 ± 0.3 14.2 ± 12.5 < 0.0001
INR 1.0 ± 0.1 1.8 ± 0.5 < 0.0001
AST (U/L) 27.0 ± 8.4 134.2 ± 78.2 < 0.0001
ALT (U/L) 26.0 ± 9.9 64.4 ± 78.2 < 0.0001
Albumin (g/dL) 3.9 ± 0.6 2.9 ± 0.7 < 0.0001
Creatinine (mg/dL) 0.8 ± 0.2 1.1 ± 1.0 0.0143
MELD score 6.8 ± 1.5 22.4 ± 7.6 < 0.0001
Total drinks in the past 30 days (TLFB) 383.3 ± 294.2 232.3 ± 263.0 0.0004
AUDIT score 29.5 ± 6.7 22.8 ± 9.2 0.0001
BMI, body mass index; WBC, white blood cell; INR, international normalized ratio; AST, aspartate transaminase; ALT, alanine transaminase; 
MELD, Model For End-Stage Liver Disease; TLFB, Time Line Follow-Back; AUDIT, Alcohol Use Disorders Identification Test.
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Table 3
Number of alcoholic hepatitis cases (n = 90) and controls (n = 93) for various rs738409 genotypes.
C/C G/C G/G MAF
Controls 57 32 4 0.215
Cases 39 41 10 0.339
NB: The SNP is oriented on the minus strand; i.e., it can be argued that rs738409(G) is actually the common allele. MAF, minor allele frequency.
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Table 4
Mortality during the first 12 months after diagnosis in alcoholic hepatitis cases (n = 90) for various rs738409 
genotypes.
C/C G/C G/G MAF
Survived 31 32 8 0.338
Died 8 9 2 0.342
MAF, minor allele frequency.
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